natgillin/translations-raw huggingface dataset:
In combination with other medicines the usual dose for adults may be less than 1250 mg/m2 of body surface area, and you may need to take the tablets over a different time period (e.g. every day, with no rest period). 
V kombinaciji z drugimi zdravili je lahko običajni odmerek za odrasle manjši od 1250 mg/m2 telesne površine.
Do not take Xeloda: 
Zdravilo Xeloda je indicirano:
• skin rash, hair loss (alopecia), skin reddening, dry skin, itching (pruritus), skin discolouration, skin loss, skin inflammation, nail disorder pain in the joints, or in the limbs (extremities), chest or back fever, swelling in the limbs, feeling ill 
• kožni izpuščaj, izpadanje las (alopecijo), pordevanje kože, suho kožo, srbenje (pruritus), razbarvanje kože, izgubo kože, vnetje kože, spremembe na nohtih,
Hepatic failure (rare), Cholestatic hepatitis (rare) 
Bolezni jeter, žolčnika in žolčevodov hiperbilirubinem ija, nenormalni testi jetrne funkcije zlatenica odpoved jeter (redki), holestatični hepatitis (redki)
Hepatic impairment. 
Bolniki z ledvično okvaro.
A total of 156 patients were randomised to treatment with 5-FU (800 mg/m2 per day, continuous infusion on days 1 to 5 every 3 weeks) and cisplatin (80 mg/m2 as a 2-hour infusion on day 
V zdravljenje s 5-FU (800 mg/m2 na dan, v kontinuirani infuziji od 1. do 5. dne vsake 3 tedne) in cisplatinom (80 mg/m2, v 2-urni infuziji 1. dan, vsake 3 tedne) pa so skupno randomizirali 156 bolnikov.
Hepatobiliary disorders 
oralni herpes
600 mg/ m intravenous 22 hr 
sledi 600 mg/m intravensko 22 h placebo ali bevacizumab
+Neutropenia, +Leucopenia, Anaemia, +Neutropenic fever, Thrombocytopenia 
+anemija, zvišana telesna temperatura z nevtropenijo, trombocitopenija depresija kostnega mozga,
• Xeloda 500 mg film-coatedtablets: Each tablet contains 500 mg capecitabine 
• Xeloda 500 mg filmsko obložene tablete Ena tableta vsebuje 500 mg kapecitabina.
Lacrimation increased, Conjunctivitis, Eye irritation 
• vnetje oči, povečano solzenje, rdeče oči (konjunktivitis),
• Xeloda 150 mg film-coated tablets: Each tablet contains 150 mg capecitabine 
• Xeloda 150 mg filmsko obložene tablete Ena tableta vsebuje 150 mg kapecitabina.
PRIMARY ANALYSI S XELOX/XELOX+P/ XELOX+BV (EPP*: N=967; ITT**: N=1017) 
XELOX/XELOX + P/
Xeloda 500 mg film-caoted tablets 
Xeloda 500 mg filmsko obložene tablete kapecitabin
You must not take Xeloda if you are pregnant or think you might be. 
Če ste noseči ali če obstaja sum na nosečnost, zdravila Xeloda ne smete jemati.
You must inform your doctor if you know that you have an allergy or over-reaction to this medicine, 
Če imate preobčutljivostno reakcijo na to zdravilo, obvestite zdravnika;
The film-coated tablets are light peach tablets of biconvex, oblong shape with the marking ‘150' on the one side and ‘Xeloda' on the other side 
Filmsko obložene 150-mg tablete Xeloda so svetlo breskove barve, bikonveksne in podolgovate oblike z oznako “150” na eni strani in “Xeloda” na drugi strani.
Light peach film-coated tablet of biconvex, oblong shape with the marking ‘150' on the one side and ‘Xeloda' on the other side. 
Svetlo breskove barve, bikonveksne in podolgovate oblike z oznako “150” na eni strani in “Xeloda” na drugi strani.
The film-coated tablets are peach tablets of biconvex, oblong shape with the marking ‘500' on the one side and ‘Xeloda' on the other side. 
Filmsko obložene 500-mg tablete Xeloda so breskove barve, bikonveksne in podolgovate oblike z oznako “500” na eni strani in “Xeloda” na drugi strani.
• headache, sleepiness, dizziness, abnormal sensation in the skin (numbness or tingling sensation), taste changes eye irritation, increased tears, eye redness (conjunctivitis) inflammation of the veins (thrombophlebitis), shortness of breath, nose bleeds, cough, runny nose cold sores or other herpes infections infections of the lungs or respiratory system (e.g. pneumonia or bronchitis) 
Bolezni kože in podkožja palmarnoplantarna eritrodisestezija kožni izpuščaj, alopecija, eritem, suha koža, pruritus, hiperpigmentaci ja kože, makulozni izpuščaj, luščenje kože, dermatitis, motnje pigmentacije, spremembe na nohtih žulj, razjede na koži, kožni izpuščaj, urtikarija, fotosenzitivne reakcije, palmarni eritem, oteklost obraza, purpura, kožna reakcija po obsevanju eritematozni lupus s spremembami na koži (redki), hude kožne reakcije, kot sta StevensJohnsonov sindrom in toksična epidermalna nekroliza (zelo redki) (glejte poglavje 4.4)
150 mg 500 mg 
Enkratni odmerek (mg) 150 mg 500 mg
Peach film-coated tablet of biconvex, oblong shape with the marking ‘500' on the one side and ‘Xeloda' on the other side. 
Breskove barve, bikonveksne in podolgovate oblike z oznako “500” na eni strani in “Xeloda” na drugi strani.
Mucosal inflammation, Pain in limb, Pain, Chills, Chest pain, Influenza-like illness, +Fever, Infusion related reaction, Injection site reaction, Infusion site pain, Injection site pain 
+zvišana telesna temperatura, z infuzijo povezana reakcija, reakcija na mestu injiciranja, bolečina na mestu infundiranja, bolečina na mestu injiciranja
Hypokalaemia, Appetite disorder, Malnutrition, Hypertriglyceridaemia, 
Presnovne in prehranske motnje anoreksija dehidracija, zmanjšanje telesne mase sladkorna bolezen, hipokaliemija, motnje apetita, podhranjenost, hipertrigliceridemija
Pulmonary embolism, Pneumothorax, Haemoptysis, Asthma, Dyspnoea exertional 
Bolezni dihal, prsnega koša in mediastinalne ga prostora dispneja, epistaksa, kašelj, rinoreja pljučna embolija, pnevmotoraks, hemoptiza, astma, dispneja ob naporu
604 patients were randomised to treatment with 5-FU and leucovorin (Mayo regimen: 20 mg/m2 leucovorin intravenous followed by 425 mg/m2 intravenous bolus 5-FU, on days 1 to 5, every 28 days). 
V teh študijah so 603 randomizirane bolnike zdravili s kapecitabinom v tritedenskem ciklu jemanja 1.250 mg/m2/dvakrat na dan 14 dni, čemur je sledil enotedenski premor, 604 randomizirane bolnike pa s 5-FU in levkovorinom (shema Mayo: 20 mg/m2 levkovorina intravensko, sledilo je 425 mg/m2 5-FU v obliki intravenskega bolusa vsakih 28 dni - na prvi do peti dan).
Contusion 
Zdravljenje
There are no side effects caused by stopping treatment with capecitabine. 
Če ste prenehali jemati zdravilo Xeloda Po prenehanju zdravljenja s kapecitabinom se ne pojavijo neželeni učinki.
During pregnancy and lactation, 
• če ste noseči ali dojite,
Xeloda 500 mg film-coated tablets. 
Xeloda 500 mg filmsko obložene tablete
In patients with severe renal impairment (creatinine clearance below 30 ml/min), Recent or concomitant treatment with brivudine (see section 4.4 and 4.5 for drug-drug interaction), 
• Nedavno ali sočasno zdravljenje z brivudinom (glede medsebojnega delovanja med zdravili glejte poglavji 4.4 in 4.5).
- ECF: epirubicin (50 mg/ m2 as a bolus on day 1 every 3 weeks), cisplatin (60 mg/m2 as a two hour infusion on day 1 every 3 weeks) and 5-FU (200 mg/m2 daily given by continuous infusion via a central line). 
- ECF: epirubicin (50 mg/m2 kot bolus 1. dan vsake 3 tedne), cisplatin (60 mg/m2 v 2-urni infuziji 1. dan vsake 3 tedne) in 5-FU (200 mg/m2 na dan v kontinuirani infuziji skozi centralni venski kateter); - ECX: epirubicin (50 mg/m2 kot bolus 1. dan vsake 3 tedne), cisplatin (60 mg/m2 v 2-urni infuziji 1. dan vsake 3 tedne) in kapecitabin (625 mg/m dvakrat na dan neprekinjeno); - EOF: epirubicin (50 mg/m2 kot bolus 1. dan vsake 3 tedne), oksaliplatin (130 mg/m2 v 2-urni infuziji 1. dan vsake tri tedne) in 5-FU (200 mg/m2 na dan v kontinuirani infuziji skozi centralni venski kateter); - EOX: epirubicin (50 mg/m2 kot bolus 1. dan vsake 3 tedne), oksaliplatin (130 mg/m2 v 2-urni infuziji 1. dan vsake tri tedne) in kapecitabin (625 mg/m2 dvakrat na dan neprekinjeno).
• tiredness 
XELOX
Ventricular fibrillation (rare), QT prolongation (rare), Torsade de pointes (rare), Bradycardia (rare), Vasospasm (rare) 
• določene tipe aritmije (vključno z ventrikularno fibrilacijo, torsade de pointes in bradikardijo),
PC: 
PPP ITT
Roche (Hellas) A.E. 
Roche Norge AS
• Repeat steps 8, 9, 10 and 11. 
• Ponovite 8., 9., 10. in 11. korak.
Tell your doctor immediately 
Takoj obvestite zdravnika:
If this happens, you may be able to feel these pieces on your tongue. 
Če pride do tega, jih boste morda začutili na jeziku.
Approximately 41% of patients had severe COPD. 
Približno 41 % bolnikov je imelo hudo KOPB.
This ensures that there is always enough medicine in your body to help you breathe more easily throughout the day and night. 
Tako zagotovite, da je v telesu vedno dovolj zdravila, da vam olajša dihanje preko dneva in noči.
If this happens: 
Če pride do tega:
• Inhale the medicine again by repeating steps 8 and 9. 
• Ponovno poskusite inhalirati zdravilo, tako da ponovite 8. in 9. korak.
If the capsule is empty, there is no need for concern. 
Če je kapsula prazna, ni nobenega razloga za zaskrbljenost.
Keep it dry. 
Pazite, da ostane suh.
Clean your inhaler once a week. 
Inhalator očistite enkrat na teden.
• cold-like symptoms. 
• prehladu podobni simptomi.
The bronchodilator effect did not depend on the time of dosing, morning or evening. 
Bronhodilatatorno delovanje ni bilo odvisno od časa odmerjanja, t.j zjutraj ali zvečer.
Not all pack sizes or strengths may be available in your country. 
V vaši državi morda niso na voljo vse jakosti oziroma velikosti pakiranj.
The chances of the capsule shattering will be increased if the capsule is accidentally pierced more than once (step 6). 
Možnost, da se kapsula tako zdrobi, je večja, če kapsulo nehote predrete več kot enkrat (6. korak).
The maximum dose is 300 microgram once daily. 
Najvišji odmerek je 300 mikrogramov enkrat dnevno.
These may be signs of a condition called bronchospasm. 
To so lahko znaki stanja, ki ga imenujemo bronhospazem.
Patients should be instructed on how to administer the product correctly. 
Bolnike je treba poučiti, kako naj si pravilno aplicirajo zdravilo.
• Hold your breath for at least 5-10 seconds or as long as you comfortably can while taking the inhaler out of your mouth. 
• Zadržite dih vsaj za 5-10 sekund oziroma tako dolgo, kolikor zmorete, in medtem vzemite ustnik iz ust.
Steady state was achieved within 12 to 14 days. 
Do stanja dinamičnega ravnovesja je prišlo v 12 do 14 dneh.
• Breathe in rapidly but steadily and as deeply as you can. 
• Hitro in enakomerno vdihnite, kolikor globoko morete.
This medicine contains lactose (milk sugar). 
To zdravilo vsebuje laktozo (mlečni sladkor).
Date of first authorisation: 30 November 2009 Date of latest renewal: 18 September 2014 
Datum zadnjega podaljšanja: 18. september 2014
These were in the vast majority mild or moderate and became less frequent if treatment was continued. 
V veliki večini so bili ti učinki blagi ali zmerni, njihova pogostnost pa se je z nadaljevanjem zdravljenja zmanjšala.
An additional adverse reaction was tremor (common). 
Pojavil se je dodatni neželeni učinek, in sicer tremor (pogosto).
Within each system organ class, adverse reactions are ranked by frequency in descending order according to the following convention: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data). 
Znotraj vsakega organskega sistema so neželeni učinki razvrščeni po padajoči pogostnosti v skladu z naslednjim dogovorom: zelo pogosti (≥1/10); pogosti (≥1/100 do <1/10); občasni (≥1/1.000 do <1/100); redki (≥1/10.000 do <1/1.000); zelo redki (<1/10.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Therefore the frequency was calculated from clinical trial experience. 
Iz tega razloga je pogostnost izračunana na podlagi izkušenj v kliničnih študijah.
You will feel tired, very thirsty and hungry (without gaining weight) and will pass more urine than usual (common). 
Čutili boste utrujenost, hudo žejo in lakoto (brez povečanja telesne mase), poleg tega pa boste odvajali več urina kot običajno
Patients who do not experience improvement in breathing should be asked if they are swallowing the medicine rather than inhaling it. 
Bolnike, pri katerih ne pride do izboljšanja dihanja, je treba vprašati, ali zdravilo morda pogoltnejo namesto da bi ga inhalirali.
The mean age of patients was 64 years, with 48% of patients aged 65 years or older, and the majority (80%) was Caucasian. 
Povprečna starost bolnikov je znašala 64 let, pri čemer je bilo 48 % bolnikov starih 65 let ali več in je bila večina (80 %) belcev.
After intravenous infusion the volume of distribution of indacaterol during the terminal elimination phase was 2557 litres indicating an extensive distribution. 
Po intravenski infuziji je bil volumen porazdelitve indakaterola v obdobju končne faze izločanja 2557 litrov, kar kaže na obsežno porazdelitev.
Do this only once. 
Pritisnite samo enkrat.
The magnitude of response was generally greater than seen with active comparators (Table 2). 
Obseg odziva je bil večinoma večji kot pri aktivnih primerjalnih zdravilih (preglednica 2).
In case such effects occur, treatment may need to be discontinued. 
Če pride do takega vpliva, je včasih treba zdravljenje prekiniti.
4,764 patients were exposed to indacaterol up to one year at doses up to twice the maximum recommended dose. 
4.764 bolnikov je bilo izpostavljenih indakaterolu v trajanju do enega leta z uporabo odmerkov, ki so dosegali do dvakratno vrednost najvišjega priporočenega odmerka.
Use your inhaler at the same time each day, the effects last for 24 hours. 
Inhalator uporabljajte vsak dan ob istem času, saj učinek zdravila traja 24 ur.
Most people are able to empty the capsule with one or two inhalations. 
Večina ljudi lahko izprazni kapsulo z eno ali z dvema vdihoma.
Do not press the side buttons more than once. 
Stranskih gumbov ne pritiskajte več kot enkrat.
Pharmacokinetic data were obtained from a number of clinical studies, from healthy volunteers and COPD patients. 
Farmakokinetični podatki izvirajo iz številnih kliničnih študij, v katere so bili vključeni zdravi prostovoljci in bolniki s KOPB.
• Then breathe out. 
• Nato izdihnite.
Hold breath: 
Zadržite dih:
Oslif Breezhaler should only be used during pregnancy if the expected benefits outweigh the potential risks. 
Uporaba zdravila Oslif Breezhaler je v času nosečnosti upravičena le v primeru, da pričakovane koristi presegajo možna tveganja.
If a dose is missed the next dose should be taken at the usual time the next day. 
V primeru izpuščenega odmerka je treba naslednji odmerek vzeti naslednji dan ob običajnem času.
The dose should only be increased on medical advice. 
Odmerek je mogoče zvišati samo po nasvetu zdravnika.
The clinical development programme included one 12-week, two six-month (one of which was extended to one year to evaluate safety and tolerability) and one one-year randomised controlled studies in patients with a clinical diagnosis of COPD. 
Klinični razvojni program je obsegal eno 12-tedensko, dve 6-mesečni (od katerih so eno podaljšali na eno leto, da bi ocenili varnost in prenosljivost zdravila) in eno enoletno randomizirano kontrolirano študijo pri bolnikih s klinično diagnozo KOPB.
Absolute bioavailability of indacaterol after an inhaled dose was on average 43% to 45%. 
Absolutna biološka uporabnost indakaterola po inhaliranju odmerka je bila povprečno od 43 do 45 %.
Always release the push buttons before inhalation. 
Pred inhaliranjem vedno izpustite potisne gumbe.
Your doctor may tell you to use the 150 microgram capsule or the 300 microgram capsule depending on your condition and on how you respond to the treatment. 
Zdravnik vam lahko naroči, da uporabljate kapsule s 150 mikrogrami ali s 300 mikrogrami, kar je odvisno od vaše bolezni in odziva na zdravljenje.
There are no data from the use of indacaterol in pregnant women available. 
Ni podatkov o uporabi indakaterola pri nosečnicah.
If you do, don't worry. 
Če tudi vi kašljate, naj vas to ne skrbi.
All these findings occurred at exposures sufficiently in excess of those anticipated in humans. 
Do vseh teh izsledkov je prišlo pri izpostavljenosti zdravilu, ki je v zadostni meri presegla izpostavljenost, predvideno pri ljudeh.
1.0 b a n/e a 
1,0 b a n/o a
Limited treatment experience is available in individuals of African descent. 
Izkušenj z zdravljenjem posameznikov afriškega rodu je malo.
Renal clearance of indacaterol was, on average, between 0.46 and 1.20 litres/hour. 
Ledvični očistek indakaterola je bil v povprečju med 0,46 in 1,20 litra/uro.
The capsules contain lactose. 
Kapsule vsebujejo laktozo.
• if you get high levels of sugar in your blood (diabetes). 
• če se vam zviša raven glukoze v krvi (sladkorna bolezen).
• Pierce the capsule by firmly pressing together both side buttons at the same time. 
• Kapsulo predrete tako, da oba stranska gumba istočasno močno stisnete skupaj.
Do not use this medicine after the expiry date which is stated on the carton and blister after “EXP”. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in pretisnem omotu poleg oznake "EXP".
Percentage of patients who achieved MCID SGRQ† 
41 c odstotek bolnikov, ki so dosegli MCID SGRQ†
You may notice that your heart is beating faster than usual, or you may have a headache, feel drowsy, feel nauseous or have to vomit. 
Morda boste opazili, da vam srce bije hitreje kot običajno, morda vas bo bolela glava ali boste zaspani ali pa vam bo slabo in morda boste bruhali.
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before using this medicine. 
Če vam je zdravnik povedal, da imate intoleranco za nekatere sladkorje, se pred uporabo tega zdravila posvetujte s svojim zdravnikom.
Indacaterol is a chiral molecule with R-configuration. 
Indakaterol je kiralna molekula z R-konfiguracijo.
These were reported voluntarily from a population of uncertain size, and it is therefore not always possible to reliably estimate the frequency or establish a causal relationship to exposure to the medicinal product. 
Ker gre za spontano sporočene neželene učinke iz populacije nedoločljive velikosti, ni vedno mogoče zanesljivo oceniti njihove pogostnosti ali ugotoviti vzročne povezanosti z izpostavljenostjo zdravilu.
Release the side buttons fully. 
Stranska gumba povsem izpustite.
Never place a capsule directly into the mouthpiece. 
Kapsule nikoli ne nameščajte neposredno na ustnik.
The frequency of notable QTcF intervals [i.e. >450 ms (males) and >470 ms (females)] and reports of hypokalaemia were similar to placebo. 
O opaznih intervalih QTcF [kar pomeni >450 ms (pri moških) in >470 ms pri ženskah] in o hipokaliemiji so poročali s podobno pogostnostjo kot pri uporabi placeba.
The in vitro human serum and plasma protein binding was 94.1-95.3% and 95.1-96.2%, respectively. 
In vitro je vezava na proteine v humanem serumu 94,1-95,3 %, na proteine v humani plazmi pa 95,1-96,2 %.
In Phase III clinical studies, healthcare providers observed during clinic visits that on average 17-20% of patients experienced a sporadic cough that occurred usually within 15 seconds following inhalation and typically lasted for 5 seconds (about 10 seconds in current smokers). 
V fazi III kliničnih študij so zdravstveni delavci na kliničnih obiskih bolnikov opažali, da je v povprečju pri 17-20 % bolnikov prišlo do občasnega kašlja, običajno v 15 sekundah po inhalaciji, z značilnim trajanjem 5 sekund (oziroma približno 10 sekund pri bolnikih, ki so bili kadilci).
Tell your doctor immediately if your COPD symptoms (breathlessness, wheezing, cough) do not improve or get worse. 
Takoj obvestite zdravnika, če se simptomi KOPB (zadihanost, piskanje v pljučih, kašelj) ne izboljšajo ali če se poslabšajo.
Do not blow into the mouthpiece. 
Ne pihajte v ustnik.
If you experience coughing briefly after inhaling the medicine, do not worry. 
Če kašljate kmalu po inhaliranju, naj vas to ne skrbi.
If there is powder left in the capsule: 
Če je v kapsuli še prašek:
Indacaterol was excreted into human faeces primarily as unchanged parent substance (54% of the dose) and, to a lesser extent, hydroxylated indacaterol metabolites (23% of the dose). 
Indakaterol se je izločal v blato predvsem v nespremenjeni osnovni obliki (54 % odmerka), v manjši meri pa še v obliki hidroksiliranih metabolitov indakaterola (23 % odmerka).
In isolated human bronchus, indacaterol has a rapid onset of action and a long duration of action. 
V izoliranem humanem bronhusu indakaterol začne delovati hitro in deluje dolgotrajno.
An increase in the daily dose of Oslif Breezhaler beyond the maximum dose of 300 microgram is not appropriate. 
Zviševanje dnevnega odmerka zdravila Oslif Breezhaler preko najvišjega odmerka 300 mikrogramov ni primerno.
Of these patients, 2,611 were on treatment with 150 microgram once daily and 1,157 on treatment with 300 microgram once daily. 
Izmed teh bolnikov jih je 2.611 prejemalo odmerek 150 mikrogramov enkrat dnevno, 1.157 pa odmerek 300 mikrogramov enkrat dnevno.
Study design with a: indacaterol 150 microgram, salmeterol and placebo; 
Zasnova študije z uporabo a: indakaterola 150 mikrogramov, salmeterola in placeba;
The most common adverse reactions at the recommended doses were nasopharyngitis (14.3%), upper respiratory tract infection (14.2%), cough (8.2%), headache (3.7%) and muscle spasms (3.5%). 
Najbolj pogosti neželeni učinki pri uporabi priporočenih odmerkov so bili nazofaringitis (14,3 %), okužbe zgornjih dihal (14,2 %), kašelj (8,2 %), glavobol (3,7 %) in mišični krči (3,5 %).
Do not inhale a double dose to make up for a forgotten dose. 
Ne inhalirajte dvojnega odmerka, če ste pozabili vzeti prejšnji odmerek.
As long as the capsule is empty, you have received enough of your medicine. 
Če ste kapsulo izpraznili, ste prejeli dovolj zdravila.
Close the inhaler: Close the inhaler until you hear a “click”. 
Zaprite inhalator: Ko zaprete inhalator, slišite "klik".
You may get all or most of the following: sore throat, runny nose, blocked nose, sneezing, coughing, headache. 
Lahko se pojavijo vsi ali pa večina naslednjih simptomov: vnetje grla oziroma žrela, izcedek iz nosu, zamašen nos, kihanje, kašljanje, glavobol.
Put the empty capsule in your household waste. 
Prazno kapsulo odvrzite med gospodinjske odpadke.
Systemic exposure results from a composite of pulmonary and gastrointestinal absorption; about 75% of systemic exposure was from pulmonary absorption and about 25% from gastrointestinal absorption. 
K sistemski izpostavljenosti prispevata tako pljučna kot gastrointestinalna absorpcija; okoli 75 % sistemske izpostavljenosti je prispevala pljučna absorpcija in okoli 25 % gastrointestinalna absorpcija.
Effects on cardiac electrophysiology 
Učinki na elektrofiziologijo srca
In clinical studies which included urine collection, the amount of indacaterol excreted unchanged via urine was generally lower than 2% of the dose. 
V kliničnih študijah, v katerih so prestrezali urin, je bil delež nespremenjenega indakaterola, ki se je izločil z urinom, večinoma manjši od 2 % odmerka.
Do not use Oslif Breezhaler - if you are allergic to indacaterol or any of the other ingredients of this medicine (listed in section 6). 
Ne uporabljajte zdravila Oslif Breezhaler - če ste alergični na indakaterol ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
• Open the inhaler to see if any powder is left in the capsule. 
• Odprite inhalator in poglejte, ali je v kapsuli ostalo še kaj praška.
Indacaterol has not been shown to cause interactions with medicinal products administered concomitantly. 
Ne kaže, da bi indakaterol povzročal interakcije s sočasno uporabljanimi zdravili.
Maximum plasma concentration and overall systemic exposure increase with age but no dose adjustment is required in elderly patients. 
S starostjo se zviša najvišja koncentracija v plazmi in poveča sistemska izpostavljenost zdravilu, vendar prilagajanje odmerjanja pri starejših bolnikih ni potrebno.
It was observed with a higher frequency in female than in male patients and in current smokers than in ex-smokers. 
Kašelj so pogosteje opažali pri ženskah kot pri moških in pri bolnikih, ki so bili kadilci, v primerjavi s tistimi, ki so prenehali kaditi.